

# European Partnership on Animal Health & Welfare

Hein Imberechts (Sciensano) & Jean-Charles Cavitte (DG-AGRI)

A general presentation of the Partnership AH&W

November 2022

### **PAHW: WHY a Partnership?**



- No single country has the capacity on its own to address the future challenges in AH&W (developing new vaccines and diagnostic tools, understanding epidemiology of diseases etc.).
  - Bring most AH&W actors together, also international ones.
  - Strengthen cooperation and synergy and avoid duplication of work among countries.
- Increased need for data management, not least for broad surveillance and preparedness.
- Development and validation and uptake of products, require a continuum in the R&I chain from low to high TRLs ...
- To cope with an insufficient AH industry interest or investments in certain domains.

An <u>ambitious partnership</u> approach around shared priorities, rather than scattered topics in Horizon Europe work programmes.

# **PAHW: building on existing initiatives**

- History of successful (but relatively modest) EU public-public research partnerships
  - ERA-NETs: FP7 EMIDA (AH), ANIHWA (AHW): €70mio in joint transnational calls
  - H2020 ICRAD: 1<sup>st</sup> call over €20mio; 2<sup>nd</sup> call ongoing (over €12M)
  - For AW: also SusAn and Core-Organic
- These were based on SCAR CWG Animal Health and Welfare (over 20 countries)
  - Also SCAR FISH
- One Health European Joint Programme, €90mio co-fund
- International Research Consortium (STAR-IDAZ IRC), opening new avenues for global cooperation.
- (ETP GAH and) **Discontools**











 $\geq$ 

*<del></del>* 

### **Overview of 49 candidate European Partnerships**

#### PILLAR II - Global challenges & European industrial competitiveness

PILLAR III - Innovative Europe

CLUSTER 1: Health	CLUSTER 4: Digital, Industry & Space	CLUSTER 5: Climate, Energy & Mobility	CLUSTER 6: Food, Bioeconomy, Agriculture,	EIT	SUPPORT TO INNOVATION ECOSYSTEMS	
Innovative Health Initiative	Key Digital Technologies	Clean Hydrogen	Circular Bio-based Europe	InnoEnergy	Innovative SMEs	
Global Health Partnership	Smart Networks & Services	Clean Aviation	Rescuing Biodiversity to Safeguard Life on Earth	Climate		
Transformation of health systems	High Performance	Single European Sky ATM Research 3	Climate Neutral,	Digital		
Chemicals risk	Computing	Europe's Rail	Sustainable & Productive Blue Economy	Food		
assessment	European Metrology (Art. 185)	Connected and Automated Mobility (CCAM)	Water4All	Health		
ERA for Health	AI-Data-Robotics		Animal Health & Welfare*	Raw Materials		
Rare diseases*	Photonics	Batteries	Accelerating Farming	Manufacturing		
One-Health Anti Microbial Resistance*	Made in Europe	Zero-emission waterborne transport	Systems Transitions*	Urban Mobility		
Personalised Medicine*	Clean steel – low-carbon steelmaking	Zero-emission road transport	Agriculture of Data* Safe & Sustainable Food	Cultural and Creative Industries		
Pandemic Preparedness* Co-funded or co- programmed	Processes4Planet	Built4People	System*	CROSS-PILLARS II AND I		
programmed	Global competitive space systems**					
Institutionalised Partnerships (A		Driving Urban Transitions		European Open Science Cloud		

Institutionalised partnerships / EIT

Co-Programmed

Co-Funded

\* Calls with opening dates in 2023-24

\*\* Calls with opening dates not before 2022



# **Co-Funded EUP AH&W: the content**

#### Scope

- Animal infectious diseases, including consequences for public health; animal welfare.
- Livestock (terrestrial and aquatic animals); wildlife and companion animals where relevant.

### • Aim

 $\geq$ 

30

CWG AH

- Reinforce preparedness against upcoming and emerging threats for both animals and humans.
- Promote and strengthen animal welfare.
- Generate innovative methodologies and products.
- Support evidence based policy making.
- Strengthen ERA and leverage resources in animal health and welfare.
- Impact
  - Socio-economic & ecology impact when the burden of animal infectious diseases reduced.
  - Science & Technology: increased knowledge in AH&W.
  - Policy: national, European, international.









### **Vision of the Partnership**

The vision of the PAHW is to provide society with reassurance on the **control of infectious animal diseases** with appropriate means, where **antimicrobials are prudently used**, where **animal welfare** is respected and improved, thus contributing to **sustainable livestock farming** and the protection of **public health** and the **environment**.

This vision and ambition will be achieved through strengthened cooperation between **public** research and innovation entities, and the association of relevant partners, **including the animal health industry**.

DRIVERS	Socie Vulnerable se societal recog impro	ector with a gnition to be	New techno innov opportunitie to overcom			<u>Economic</u> : Return on investment to be enhanced to stimulate funding		Political: Animal health, welfare and food regulations at EU level, Tripartite Action Plan AMR, Green Deal, new CAP, etc. enforce rigid restrictions		
GEN OBJ.	To better control animal infectious diseases and reinforce the preparedness of all actors				To place animal welfare at the foreground of animal production					
SPECIFIC OBJ.	To facilitate the cooperation between all relevant actors on animal health and welfare To boost research and increase evidence-base to develop products and tools for AH&W				e-base to and tools	To enhance cross-sector collaboration in a One Health-One Welfare perspective To strengthen the dissemination and uptake of outputs				
OPERATIONAL OBJECTIVES	Surveillance systems for animal health and welfare	Diagnostic procedures and tools for monitoring of animal health	Procedures and tools for monitoring of animal welfare	Adapt risk assessment and alert communi- cation to new needs	Guidelines and preventive tools to fight animal infectious diseases on farm	Guidelines and prototype solutions to advance animal welfare	Interven- tions and treatments against animal infectious diseases	Vaccines, adjuvants and immuno- modulators	Access to veterinary vaccines, interven- tions and treatments	Integrated approach on animal health and welfare, incl. socio- economic aspects
IMPACT	<ul> <li>Scientific:</li> <li>Improved coordination of all actors in animal health and welfare, public health and the environment</li> <li>Increased investments in research and innovation, infrastructures, education and training, and services in animal health and welfare</li> <li>State-of-art science to improve animal health and welfare, and protect public health</li> </ul>			<ul> <li>Societal:</li> <li>Heightened food safety and security, and reinforced capacity of the livestock sector to meet the objectives of related political priorities</li> <li>Improved protection of public health by capacity to reduce zoonoses and reduce inappropriate use of traditional antimicrobials</li> <li>Improved preparedness of all actors and stakeholders and provision of means for farmers and other actors to manage their activities in a way to prevent and control AIDs</li> <li>Improved societal perception of animal production by better addressing animal welfare across the entire chain.</li> </ul>			priorities e zoonoses and provision of ties in a way to	<ul> <li>Economical / Technological</li> <li>Contribute to a more healthy, sustainable and resilient livestock and aquaculture sector</li> <li>Create a more dynamic animal healthcare industry</li> <li>Protect economic viability of livestock and aquaculture farming systems</li> <li>Uptake by all actors of tools and methods to prevent and control animal infectious diseases and strengthen animal welfare</li> </ul>		

AID + zoonoses Wildlife AMR of animal pathoge FAIR data AH&W Animal welfare

• 001. To design and health and welfare.

Research on pathogens Direct-indirect; pen-site DIVA, dead/alive Multi-target Sampling

- OO2. To develop **diagnostic** procedures, monitoring of **animal health.**
- OO3. To develop procedures, methodologies and tools to sup animal welfare.
- OO4. To adapt **risk assessment and alert communication** to the new needs in animal health and welfare.

See PAHW Dossier on EU website: <u>link</u>

Precision farming Welfare during transport Welfare at slaughter Psychological indicator

### **is** for animal

Methodologies Wildlife & human interventions Genomic surveillance AW surveillance

biectives

Biosecurity Prudent use AM Animal resilience Experimental farms

# bjectives

AW and farm sustainability Welfare indicators Feeding & breeding

- OO5. To develop guidelines c diseases on farm and during
- OO6. To develop guidelines and prototype solutions that ac farm, during transport and at the end of life.

Basic research (TRL1-2) Develop tools on farm, models, bio-informatics Uptake by industry

• OO7. To develop new *interventions and treatments*, or improve existing ones, against specific priority infectious disease of animals.

See PAHW Dossier on EU website: <u>link</u>

Study immune system Develop tools Develop & improve vaccines and immuno-modulators Uptake by industry

• 008. To develop new **vaccin** immune-modulators.

#### Monitor PAHW projects Manage IP Support regulatory process Procedures to support clinical studies

**bjectives** 

Social science studies AH and AW Study incentives and barriers among farmers Study the integration AH, AW and production

- OO9. To increase access to veterinary vaccines, intervention uptake of said vaccines interventions and treatments in the pre-
- OO10. To develop an *integrated approach* on animal health and welfare including *socio-economic aspects* of animal health and animal welfare.



EC, National & International Stakeholders

CWG AH & W

### **Proposed mixed scenario**



- External open R&I calls
  - Aiming at generating knowledge, possibly by including private partners and/or external research centres in the research, e.g. to bring in new technologies for diagnostics or vaccine development etc., to facilitate uptake by industry, or in case additional expertise is needed that is not available in the partnership consortium.
  - Organized by Funding Organizations (so called cash funding; EC co-funding as financial support to third parties).
  - All infectious diseases, both basic and applied research.
- Internal R&I calls
  - Reinforce cooperation among research centres, reference laboratories/centres (i.e. RPO), with specific mandates and expertise (e.g. regulated diseases and AMR; reference activities), or special experimental facilities; mainly integrative research; policy driven research, incl. animal welfare.
  - Limited to RPO that are member of the partnership; eligible costs are funded through inkind funding from these RPO and with EU co-funding.
- Other internal activities, i.e. reference, integrative and other joint activities.

# **Categories of activities in the EUP AH&W**

#### External open research

• Allow to include external RPO and/or private partners to bring in new technologies and additional expertise that is not available in the partnership consortium, and to facilitate uptake by industry.

#### Internal research

 Research for which the technologies and expertise are available within the consortium; to reinforce the cooperation among the partners, to strengthen their tasks for the authorities through setting up integrative research calls: capacity building, data sharing and risk assessment; policy driven research ('preparedness').

### Reference and Integrative actions

• All non-research actions that support cooperation between partners to strengthen their duties to the authorities.

### • Joint activity

• Thematic networking, education & training (summer schools, workshops, PhD, etc.), support regulatory processes, etc.



## **EUP AH&W collaboration with ICRAD**

- ERA-NET <u>ICRAD</u>: International Coordination of Research on Infectious Animal Diseases.
- An online survey on AH and AW activities performed by ICRAD.
  - Based on desk study that identified research priorities in existing European and global strategic documents.
    - Various domains in line with PAHW Dossier (intervention logic).
  - Analysis by ICRAD is ongoing; Focus Groups, a SRIA Workshop (November 2022) and broad consultation until the beginning of 2023.
  - The objective is to identify research priorities, especially for the first 2 years.
- The AH&W SRIA needs to comply with the EU criteria, a.o. a well developed intervention logic + resources; monitoring framework for assessing the progress towards the objectives; identification of other European Partnerships with which to establish a formal and regular collaboration; plans for updating the SRIA.

### **Glossary of some project terminology**

- <u>Source</u>: Horizon Europe Programme, Standard Application Form (HE Cofund) <u>link</u>
- Results/outputs/deliverables. Results are any tangible or intangible effect of the action, such as data, know-how or information. Results to which access can be given in the form of scientific publications, data or other engineered results and processes are referred to as research and other output. A deliverable is a report providing information to ensure effective monitoring of the project.
- Outcomes: The expected effects, over the medium term, of projects supported under a given topic. The results of a project should contribute to these outcomes, fostered in particular by the dissemination and exploitation measures. This may include the uptake, diffusion, deployment, and/or use of the project's results by direct target groups. Outcomes generally occur during or shortly after the end of the project.
- Impact: Wider long term effects on society (including the environment), the economy and science, enabled by the outcomes of R&I investments. It refers to the specific contribution of the project to the work programme expected impacts described in the destination.

# **Questions?**

- Please contact
  - Sven Arnouts <u>Sven.Arnouts@UGent.be</u>
  - Hein Imberechts <u>hein.imberechts@sciensano.be</u>
  - Florence Tardy <a href="mailto:florence.tardy@anses.fr">florence.tardy@anses.fr</a>
  - Jean-Charles Cavitte <u>Jean-Charles.Cavitte@ec.europa.eu</u>
  - Valerio Abbadessa <u>Valerio.Abbadessa@ec.europa.eu</u>

November 2022